Share-based Payment Arrangement, Expense of Corvus Pharmaceuticals, Inc. from 31 Mar 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Corvus Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2015 to 30 Sep 2025.
  • Corvus Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,249,000, a 70% increase year-over-year.
  • Corvus Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $4,569,000, a 65% increase year-over-year.
  • Corvus Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $3,003,000, a 40% increase from 2023.
  • Corvus Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2,147,000, a 20% decline from 2022.
  • Corvus Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2,692,000, a 36% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Corvus Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $4,569,000 $1,249,000 +$516,000 +70% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $4,053,000 $1,256,000 +$488,000 +64% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $3,565,000 $1,251,000 +$562,000 +82% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $3,003,000 $813,000 +$241,000 +42% 01 Oct 2024 31 Dec 2024 10-K 25 Mar 2025 2024 FY
Q3 2024 $2,762,000 $733,000 +$187,000 +34% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $2,575,000 $768,000 +$231,000 +43% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $2,344,000 $689,000 +$197,000 +40% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $2,147,000 $572,000 -$48,000 -7.7% 01 Oct 2023 31 Dec 2023 10-K 25 Mar 2025 2024 FY
Q3 2023 $2,195,000 $546,000 -$112,000 -17% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $2,307,000 $537,000 -$138,000 -20% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $2,445,000 $492,000 -$247,000 -33% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $2,692,000 $620,000 -$118,000 -16% 01 Oct 2022 31 Dec 2022 10-K 25 Mar 2025 2024 FY
Q3 2022 $2,810,000 $658,000 -$438,000 -40% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $3,248,000 $675,000 -$498,000 -42% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $3,746,000 $739,000 -$486,000 -40% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $4,232,000 $738,000 -$498,000 -40% 01 Oct 2021 31 Dec 2021 10-K 19 Mar 2024 2023 FY
Q3 2021 $4,730,000 $1,096,000 -$187,000 -15% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $4,917,000 $1,173,000 -$210,000 -15% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $5,127,000 $1,225,000 -$620,000 -34% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $5,747,000 $1,236,000 -$512,000 -29% 01 Oct 2020 31 Dec 2020 10-K 28 Mar 2023 2021 FY
Q3 2020 $6,259,000 $1,283,000 -$466,000 -27% 01 Jul 2020 30 Sep 2020 10-Q 01 Nov 2021 2021 Q3
Q2 2020 $6,725,000 $1,383,000 -$515,000 -27% 01 Apr 2020 30 Jun 2020 10-Q 02 Aug 2021 2021 Q2
Q1 2020 $7,240,000 $1,845,000 -$108,000 -5.5% 01 Jan 2020 31 Mar 2020 10-Q 29 Apr 2021 2021 Q1
Q4 2019 $7,348,000 $1,748,000 -$56,000 -3.1% 01 Oct 2019 31 Dec 2019 10-K 10 Mar 2022 2021 FY
Q3 2019 $7,404,000 $1,749,000 -$45,000 -2.5% 01 Jul 2019 30 Sep 2019 10-Q 29 Oct 2020 2020 Q3
Q2 2019 $7,449,000 $1,898,000 +$162,000 +9.3% 01 Apr 2019 30 Jun 2019 10-Q 30 Jul 2020 2020 Q2
Q1 2019 $7,287,000 $1,953,000 +$152,000 +8.4% 01 Jan 2019 31 Mar 2019 10-Q 30 Apr 2020 2020 Q1
Q4 2018 $7,135,000 $1,804,000 +$65,000 +3.7% 01 Oct 2018 31 Dec 2018 10-K 25 Mar 2021 2020 FY
Q3 2018 $7,070,000 $1,794,000 +$293,000 +20% 01 Jul 2018 30 Sep 2018 10-Q 29 Oct 2019 2019 Q3
Q2 2018 $6,777,000 $1,736,000 +$215,000 +14% 01 Apr 2018 30 Jun 2018 10-Q 01 Aug 2019 2019 Q2
Q1 2018 $6,562,000 $1,801,000 +$333,000 +23% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $6,229,000 $1,739,000 +$691,000 +66% 01 Oct 2017 31 Dec 2017 10-K 09 Mar 2020 2019 FY
Q3 2017 $5,538,000 $1,501,000 +$237,000 +19% 01 Jul 2017 30 Sep 2017 10-Q 01 Nov 2018 2018 Q3
Q2 2017 $5,301,000 $1,521,000 +$446,000 +41% 01 Apr 2017 30 Jun 2017 10-Q 02 Aug 2018 2018 Q2
Q1 2017 $4,855,000 $1,468,000 +$1,027,000 +233% 01 Jan 2017 31 Mar 2017 10-Q 03 May 2018 2018 Q1
Q4 2016 $3,828,000 $1,048,000 +$762,000 +266% 01 Oct 2016 31 Dec 2016 10-K 07 Mar 2019 2018 FY
Q3 2016 $3,066,000 $1,264,000 +$1,141,000 +928% 01 Jul 2016 30 Sep 2016 10-Q 02 Nov 2017 2017 Q3
Q2 2016 $1,925,000 $1,075,000 +$1,058,000 +6224% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017 2017 Q2
Q1 2016 $867,000 $441,000 +$439,000 01 Jan 2016 31 Mar 2016 10-Q 04 May 2017 2017 Q1
Q4 2015 $428,000 $286,000 01 Oct 2015 31 Dec 2015 10-K 01 Mar 2018 2017 FY
Q3 2015 $123,000 01 Jul 2015 30 Sep 2015 10-Q 03 Nov 2016 2016 Q3
Q2 2015 $17,000 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016 2016 Q2
Q1 2015 $2,000* 01 Jan 2015 31 Mar 2015 10-Q 05 May 2016 2016 Q1

Corvus Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $3,003,000 +$856,000 +40% 01 Jan 2024 31 Dec 2024 10-K 25 Mar 2025 2024 FY
2023 $2,147,000 -$545,000 -20% 01 Jan 2023 31 Dec 2023 10-K 25 Mar 2025 2024 FY
2022 $2,692,000 -$1,540,000 -36% 01 Jan 2022 31 Dec 2022 10-K 25 Mar 2025 2024 FY
2021 $4,232,000 -$1,515,000 -26% 01 Jan 2021 31 Dec 2021 10-K 19 Mar 2024 2023 FY
2020 $5,747,000 -$1,601,000 -22% 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2023 2021 FY
2019 $7,348,000 +$213,000 +3% 01 Jan 2019 31 Dec 2019 10-K 10 Mar 2022 2021 FY
2018 $7,135,000 +$906,000 +15% 01 Jan 2018 31 Dec 2018 10-K 25 Mar 2021 2020 FY
2017 $6,229,000 +$2,401,000 +63% 01 Jan 2017 31 Dec 2017 10-K 09 Mar 2020 2019 FY
2016 $3,828,000 +$3,400,000 +794% 01 Jan 2016 31 Dec 2016 10-K 07 Mar 2019 2018 FY
2015 $428,000 01 Jan 2015 31 Dec 2015 10-K 01 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.